|
1) Lang B, Vincent A. Autoimmune disorders of the neuromuscular junction. Curr Opin Pharmacol. 2009; 9: 336-40
|
|
|
|
2) Gomez AM, Van Den Broeck J, Vrolix K, et al. Antibody effector mechanisms in myasthenia gravis-Pathogenesis at the neuromuscular junction. Autoimmunity. 2010, 43: 353-70
|
|
|
|
|
|
3) 本村政勝. 重症筋無力症: 病原性のある自己抗体は何か. 脳と神経. 2010; 62: 411-8
|
|
|
|
|
|
4) Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Med. 2001; 7: 365-68
|
|
|
|
|
|
5) Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003; 126: 1-8
|
|
|
|
|
|
6) Sanders DB, El-Salem K, Massay JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003; 60: 1978-80
|
|
|
|
|
|
7) Vincent A, Bowen J, Newsom-Davis J, et al. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol. 2003; 2: 99-106
|
|
|
|
|
|
8) Vincent A, Leite MI. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol. 2005; 18: 519-25
|
|
|
|
|
|
9) 本村政勝, 福田 卓, 吉村俊朗, 他 Overview: MuSK/Dok-7. 日本臨牀. 2008; 66: 1140-8
|
|
|
|
|
10) Ohta K, Shigemoto K, Fujinami A, et al. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol. 2007; 14: 1029-34
|
|
|
|
|
|
11) Deymeer F, Gungor-Tuncer O, Yilmaz V, et al. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology. 2007; 68: 609-11
|
|
|
|
|
|
12) Tsiamalos P, Kordas G, Kokla A, et al. Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece. Eur J Neurol. 2009; 16: 925-30
|
|
|
|
|
|
13) Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U. S. experience. Muscle Nerve. 2010; 41: 370-4
|
|
|
|
|
|
14) Chang T, Gunaratne P, Gamage R, et al. MuSK-antibody-positive myasthenia gravis in a South Asian population. J Neurol Sci. 2009; 284: 33-5
|
|
|
|
|
|
15) Okada K, Inoue A, Okada M, et al. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science. 2006; 312: 1802-5
|
|
|
|
|
|
16) Kim N, Stiegler AL, Cameron TO, et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell. 2008; 135: 334-42
|
|
|
|
|
|
17) Shiraishi H, Motomura M, Yoshimura T, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol. 2005; 57: 289-93
|
|
|
|
|
|
18) McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK anti-bodies in seronegative myasthenia gravis. Ann Neurol. 2004; 55: 580-4
|
|
|
|
|
|
19) Niks EH, van Leeuwen Y, Leite MI, et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol. 2008; 195: 151-6
|
|
|
|
|
|
20) Selcen D, Fukuda T, Shen XM, et al. Are MuSK antibodies the primary cause of myasthenic symptoms？ Neurology. 2004; 62: 1945-50
|
|
|
|
|
|
21) Shigemoto K, Kubo S, Maruyama N, et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest. 2006; 116: 1016-24
|
|
|
|
|
|
22) Jha S, Xu K, Maruta T, et al. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol. 2006; 175: 107-17
|
|
|
|
|
|
23) Cole RN, Reddel SW, Gervásio OL, et al. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol. 2008; 63: 782-9
|
|
|
|
|
|
24) Niks EH, Kuks JB, Wokke JH, et al. Plomp JJ. Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia. Muscle Nerve. 2010; 42: 283
|
|
|
|
|
|
25) Lauriola L, Ranelletti F, Maggiano N, et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology, 2005; 64: 536-8
|
|
|
|
|
|
26) Leite MI, Strobel P, Jones M, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol. 2005; 57: 444-8
|
|
|
|
|
|
27) Kostera-Pruszczyk A, Kwiecinski H. Juvenile seropositive myasthenia gravis with anti-MuSK antibody after thymectomy. J Neurol. 2009; 256: 1780-1
|
|
|
|
|
|
28) Anlar B, Yilmaz V, Saruhan-Direskeneli G. Long remission in muscle-specific kinase antibody-positive juvenile myasthenia. Pediatr Neurol. 2009; 40: 455-6
|
|
|
|
|
|
29) Béhin A, Mayer M, Kassis-Makhoul B, et al. Severe neonatal myasthenia due to maternal anti-MuSK antibodies. Neuromuscul Disord. 2008; 18: 443-6
|
|
|
|
|
|
30) Oʼcarroll P, Bertorini TE, Jacob G, et al. Transient neonatal myasthenia gravis in a baby born to a mother with new-onset anti-MuSK-mediated myasthenia gravis. J Clin Neuromuscul Dis. 2009; 11: 69-71
|
|
|
|
|
|
31) Lin PT, Martin BA, Weinacker AB, et al. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve. 2006; 33: 433-5
|
|
|
|
|
|
32) Takahashi H, Kawaguchi N, Nemoto Y, et al. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive sero-negative myasthenia gravis. J Neurol Sci. 2006; 247: 239-41
|
|
|
|
|
|
33) Illa I, Diaz-Manera J, Rojas-Garcia R, et al. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. J Neuroimmunol. 2008; 201-202: 90-4
|
|
|
|
|
|
34) Yanagawa Y, Hongo Y, Shiozaki H, et al. Muscle-specific tyrosine kinase-antibody-positive myasthenic crisis with detailed electrophysiologic studies. Am J Emerg Med. 2009; 27: 754
|
|
|
|
|